|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM281612943 |
| 003 |
DE-627 |
| 005 |
20231225032032.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201705660
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0938.xml
|
| 035 |
|
|
|a (DE-627)NLM281612943
|
| 035 |
|
|
|a (NLM)29504159
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Yilong
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nanomaterials for Cancer Precision Medicine
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.02.2019
|
| 500 |
|
|
|a Date Revised 30.09.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a Medical science has recently advanced to the point where diagnosis and therapeutics can be carried out with high precision, even at the molecular level. A new field of "precision medicine" has consequently emerged with specific clinical implications and challenges that can be well-addressed by newly developed nanomaterials. Here, a nanoscience approach to precision medicine is provided, with a focus on cancer therapy, based on a new concept of "molecularly-defined cancers." "Next-generation sequencing" is introduced to identify the oncogene that is responsible for a class of cancers. This new approach is fundamentally different from all conventional cancer therapies that rely on diagnosis of the anatomic origins where the tumors are found. To treat cancers at molecular level, a recently developed "microRNA replacement therapy" is applied, utilizing nanocarriers, in order to regulate the driver oncogene, which is the core of cancer precision therapeutics. Furthermore, the outcome of the nanomediated oncogenic regulation has to be accurately assessed by the genetically characterized, patient-derived xenograft models. Cancer therapy in this fashion is a quintessential example of precision medicine, presenting many challenges to the materials communities with new issues in structural design, surface functionalization, gene/drug storage and delivery, cell targeting, and medical imaging
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a biological barriers
|
| 650 |
|
4 |
|a genome sequencing
|
| 650 |
|
4 |
|a microRNA
|
| 650 |
|
4 |
|a nanomaterials
|
| 650 |
|
4 |
|a oncogenes
|
| 650 |
|
4 |
|a patient-derived xenografts
|
| 650 |
|
4 |
|a precision medicine
|
| 650 |
|
4 |
|a tumor microenvironment
|
| 650 |
|
7 |
|a MicroRNAs
|2 NLM
|
| 700 |
1 |
|
|a Sun, Shuyang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Zhiyuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Donglu
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 30(2018), 17 vom: 05. Apr., Seite e1705660
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:30
|g year:2018
|g number:17
|g day:05
|g month:04
|g pages:e1705660
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201705660
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 30
|j 2018
|e 17
|b 05
|c 04
|h e1705660
|